Keiko Yanagihara^1,*, Masato Yoshida², Kensaku Awaji², Tamami Yamakawa¹, Sena Kato¹, Miki Tamura¹, Koji Nagata³

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.073891 - 30 December 2025

Abstract Background: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have transformed the management of hormone receptor–positive/HER2–negative (HR+/HER2–) advanced breast cancer, yet evidence for elderly or poor-performance patients remains limited. This study examined real-world outcomes of palbociclib plus endocrine therapy in Asian patients, with additional subgroup analyses by age and performance status. Methods: We retrospectively analyzed 46 consecutive Asian patients with recurrent or de novo HR+/HER2− breast cancer treated with first-line palbociclib plus ET between April 2021 and March 2025. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall response rate (ORR), disease control rate (DCR), and safety.… More >

Sarra B. Shakartalla^1,2,3, Iman M. Talaat^1,2,4,*, Nival Ali¹, Shahenaz S. Salih^1,5, Zainab M. Al Shareef^1,2, Noura Alkhayyal⁶, Riyad Bendardaf^2,7,*, Sameh S. M. Soliman^1,8,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070808 - 30 December 2025

Abstract Objectives: Breast cancer (BC) is the leading cause of cancer-related mortality in women, largely due to metastasis. This study aims to explore the role of purine nucleoside phosphorylase (PNP), a key enzyme in purine metabolism, in the aggressiveness and metastatic behavior of BC. Methods: A comprehensive analysis was performed using in silico transcriptomic data (n = 2509 patients), immunohistochemical profiling of BC tissues (n = 103), and validation through western blotting in multiple BC cell lines. Gene expression and survival analyses were conducted using Tumor Immune Estimation Resource (TIMER), Gene Expression Profiling Interactive Analysis 2 (GEPIA2), and… More >

Jing Cai^1,#, Haoyun Zhu^1,#, Weiling Guo¹, Ting Huang¹, Pangzhou Chen^1,2, Wen Zhou¹, Ziyun Guan^1,3,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.069902 - 30 December 2025

Abstract Background: Therapeutic responses of breast cancer vary among patients and lead to drug resistance and recurrence due to the heterogeneity. Current preclinical models, however, are inadequate for predicting individual patient responses towards different drugs. This study aimed to investigate the patient-derived breast cancer culture models for drug sensitivity evaluations. Methods: Tumor and adjacent tissues from female breast cancer patients were collected during surgery. Patient-derived breast cancer cells were cultured using the conditional reprogramming technique to establish 2D models. The obtained patient-derived conditional reprogramming breast cancer (CRBC) cells were subsequently embedded in alginate-gelatin methacryloyl hydrogel microspheres… More >

Ashok Kumar Sah^1,*, Ranjay Kumar Choudhary^1,2, Velilyaeva Alie Sabrievna³, Karomatov Inomdzhon Dzhuraevich⁴, Anass M. Abbas⁵, Manar G. Shalabi⁵, Nadeem Ahmad Siddique⁶, Raji Rubayyi Alshammari⁷, Navjyot Trivedi⁸, Rabab H. Elshaikh¹

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.068238 - 30 December 2025

Abstract Male breast cancer (MBC) is rare, representing 0.5%–1% of all breast cancers, but its incidence is increasing due to improved diagnostics and awareness. MBC typically presents in older men, is human epidermal growth factor receptor 2 (HER2)-negative and estrogen receptor (ER)-positive, and lacks routine screening, leading to delayed diagnosis and advanced disease. Major risk factors include hormonal imbalance, radiation exposure, obesity, alcohol use, and Breast Cancer Gene 1 and 2 (BRCA1/2) mutations. Clinically, it may resemble gynecomastia but usually appears as a unilateral, painless mass or nipple discharge. Advances in imaging and liquid biopsy have More >

Xiaopan Zou^1,2, Meiyang Sun³, Xin Jiang¹, Jingze Yu², Xiaomeng Li^4,*, Bingyu Nie^1,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.066662 - 30 December 2025

Abstract Objective: Triple-negative breast cancer (TNBC) is highly aggressive and lacks an effective targeted therapy. This study aimed to elucidate the functions and possible mechanisms of action of zinc finger miz-type containing 2 (ZMIZ2) and minichromosome maintenance complex component 3 (MCM3) in TNBC progression. Methods: The relationship between ZMIZ2 expression and clinical characteristics of TNBC was investigated. In vitro and in vivo experiments were performed to investigate the role of ZMIZ2 dysregulation in TNBC cell malignant behaviors. The regulatory relationship between ZMIZ2 and MCM3 was also explored. Transcriptome sequencing was performed to elucidate possible mechanisms underlying the ZMIZ2/MCM3… More >

Chang-Eui Hong^1,2,3, Su-Yun Lyu^1,2,3,*

BIOCELL, Vol.49, No.12, pp. 2377-2397, 2025, DOI:10.32604/biocell.2025.072360 - 24 December 2025

Abstract Objective: Triple-negative breast cancer (TNBC) remains a major therapeutic challenge with limited treatment options and poor prognosis. This study aimed to investigate the synergistic anticancer effects of doxorubicin (DOX) combined with Viscum album L. var. coloratum agglutinin (VCA) and to elucidate the underlying molecular mechanisms in TNBC cells. Methods: This study evaluated the synergistic effects and mechanisms of doxorubicin (DOX) and Viscum album L. var. coloratum agglutinin (VCA) combination in MDA-MB231 TNBC cells. Cell viability, oxidative stress markers, apoptosis-related proteins, cell migration, and proliferative recovery were assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, superoxide dismutase (SOD) and nitric oxide… More >

YANG-YANG SHUAI^1,2, PEI-PEI WANG¹, HAI-JUN ZHANG², HUI AO^1,*, WEI PENG¹, HONG ZHANG^1,2,*

BIOCELL, Vol.49, No.12, pp. 2299-2333, 2025, DOI:10.32604/biocell.2025.071569 - 24 December 2025

Abstract Breast cancer ranks first among cancer-related fatalities and is the most frequent cancer in women globally. ROS plays an important role in controlling the occurrence and progression of breast cancer. Increasing reports suggest that natural products and their derivatives are beneficial for the management of breast cancer via the regulation of reactive oxygen species (ROS). A summary of the known patterns of natural products that modulate ROS against breast cancer will contribute to the discovery of more natural medicines for clinical applications and the development of new drugs. In this review, the pharmacological effects of More >

Deema Alzamil^1,2,*, Bader Alkhamees², Mohammad Mehedi Hassan^2,3

CMES-Computer Modeling in Engineering & Sciences, Vol.145, No.3, pp. 2971-3027, 2025, DOI:10.32604/cmes.2025.070867 - 23 December 2025

Abstract Breast cancer diagnosis relies heavily on many kinds of information from diverse sources—like mammogram images, ultrasound scans, patient records, and genetic tests—but most AI tools look at only one of these at a time, which limits their ability to produce accurate and comprehensive decisions. In recent years, multimodal learning has emerged, enabling the integration of heterogeneous data to improve performance and diagnostic accuracy. However, doctors cannot always see how or why these AI tools make their choices, which is a significant bottleneck in their reliability, along with adoption in clinical settings. Hence, people are adding… More >

Fu Zhang^1,2, Miao Lin^1,2, Yuancong Jiang³, Fangjian Zhou^1,2,*

European Cytokine Network, Vol.36, No.1, pp. 1-5, 2025, DOI:10.1684/ecn.2025.0500

Abstract Interleukin-33 (IL-33), a key member of the IL-1 family, plays a significant role in inflammation and cancer. Its classic receptors, ST2 and IL-1 receptor accessory protein (IL-1RAcP), are predominantly expressed in immune cells such as T helper 2 (Th2) cells and mast cells. Recent studies have highlighted the involvement of IL-33 in breast cancer, demonstrating its ability to exert dual functional effects by modulating both innate and adaptive immune responses within the tumour microenvironment. However, the precise molecular mechanisms linking IL-33 to breast cancer pathogenesis and its potential as a target for molecularly targeted therapies More >

Yuri A. Piven¹, Danila V. Sorokin², Nastassia A. Varabyeva¹, Alexandra L. Mikhaylova², Fedor B. Bogdanov², Elena V. Shafranovskaya¹, Raman M. Puzanau³, Fedor A. Lakhvich¹, Alexander M. Scherbakov^2,4,*

Oncology Research, Vol.33, No.12, pp. 4049-4072, 2025, DOI:10.32604/or.2025.067832 - 27 November 2025

Abstract Background: The most aggressive forms of breast cancer are characterized by independence from steroid hormones but a strong dependence on growth factors. In such cancer cells, oncogenic receptors, including human epidermal growth factor receptor 2 (HER2), are activated, and their targeted inhibition represents an attractive therapeutic strategy. The study aimed to develop small-molecule potential dual heat shock protein 90 (HSP90)-HER2 inhibitors and evaluate them as anticancer agents in HER2-positive cells. Methods: The research project involved obtaining a series of compounds with potential dual inhibitory activity against HSP90 and HER2 by targeted organic synthesis, which was… More > Graphic Abstract